Clinical trial
Rituximab Combined With Chemotherapy in Burkitt's Lymphoma
NCT00388193 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00388193 |
|---|---|
| Title | Rituximab Combined With Chemotherapy in Burkitt's Lymphoma |
| Official title | Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old) |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia, Burkitt's Lymphoma |
| Intervention type | Drug |
| Interventions | RITUXIMAB |
| Enrollment | 20 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2013 |
| Completion | Dec 1, 2013 |
| First posted | Oct 16, 2006 |
| Last update posted | Oct 28, 2014 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: